High-throughput preclinical assay methods and Phase I–IV human clinical trials fully compliant with the Spanish Agency of Medicines and Medical Devices (AEMPS) and EU CTR 536/2014 standards.
Barcelona has positioned itself as Europe's premier Southern hub for life sciences, driven by institutional clusters like the Barcelona Biomedical Research Park (PRBB), Hospital Clínic, and the Vall d'Hebron Institute of Oncology (VHIO).
Catalonia represents over 50% of all ongoing clinical research trials across Spain. Sponsors require rapid preclinical-to-clinical handoffs, rigorously monitored under GCP and documented within European CTIS frameworks without budget overruns.
Catalan brands leading Mediterranean botanical supplements and clinical-grade dermocosmetics demand rigorous in vitro mechanistic assays and randomized double-blind human validation to satisfy strict EFSA claim criteria.
Rising CRO overheads across Western Europe make internal pilot extraction, active constituent standardizing, and early human efficacy trials prohibitive for emerging biotech entities throughout Baix Llobregat and the Vallès technology corridors.
Benchmarking MedGence's integrated translational research against legacy transactional laboratories serving Southern Europe.
| Evaluation Parameter | MedGence Integrated CRO & CDMO | Conventional European CROs | Standard Pure Contract Manufacturers |
|---|---|---|---|
| Preclinical to Clinical Pipeline | Seamless continuity: Active compound screening → In vitro → Animal ADMET → Human Phase I-IV trials. | Fragmented: Requires contracting separate toxicology labs and clinical academic centers. | None: Limited to strictly toll processing with zero biological testing capabilities. |
| Quality Standardization Depth | Full HPTLC, HPLC-DAD/MS, GC-MS fingerprints, and validated batch stability profiling. | Standard testing; substantial additional fees for raw botanical multi-spectrum fingerprinting. | Basic assay certificates often lacking stereochemical purity or pesticide screens. |
| Supply Chain Integration | Direct proprietary pilot plants feeding scaled CDMO manufacturing in cGMP cleanrooms. | No internal manufacturing scale; studies remain confined strictly to theoretical prototypes. | High manufacturing capacity, but zero capability to optimize or design clinical formulations. |
| Time-to-Data Timeline | Preclinical cellular assays within 4–6 weeks; modular human trial preparation under 90 days. | 16–28 weeks average backlog for bioanalytical and mammalian cell toxicity evaluations. | Dependent on external client-supplied protocols and third-party trial reports. |
Translating clinical insights into high-yield, commercial-scale production requires raw material stability, cutting-edge separation technologies, and massive capacity efficiencies.
Direct origin monitoring across mainland bio-ecological zones guarantees harvest timing optimization, active marker consistency, and non-GMO sustainable botanicals with full traceability from wild-crafted or cultivated origins.
Our partner plants deploy countercurrent extraction, supercritical fluid chromatography, and macroporous resin filtration, achieving exceptional purity thresholds (>98%) while minimizing organic solvent consumption.
From microencapsulated powders for enhanced bioavailability to softgels, chewables, and enteric-coated tablets, our facility produces commercial runs up to metric tons without quality variations.
Over 14 years supporting leading global pharmaceutical conglomerates, tertiary hospital research centers, and biotechnology developers.
A systematic, phase-gated execution plan calibrated for the regulatory timelines of Spanish and European regulatory dossiers.
High-throughput in silico target affinity, enzymatic inhibition tests, cell-based bioassays to confirm biological active markers.
Development and ICH Q2(R1) validation of HPLC, GC, and HPTLC methods; residual solvent and heavy metal assay profiles.
In vivo acute LD50, sub-chronic repeated dose, Ames genotoxicity, and pharmacokinetic (ADME) bio-distribution analyses.
Phase I–IV randomized trials under GCP standards, culminating in cGMP pilot batch scale-up and commercial finished supply.
Full compliance assurance with Spanish national laws and European directives, guaranteeing acceptable data packages for submissions across Catalonia and wider EU territories.
All MedGence clinical design architectures provide standardized eCRFs, statistical analysis plans (SAP), and audited data sets fully structured for CTIS (Clinical Trials Information System) application submission.
For nutraceutical innovators developing products under Regulation (EC) 1924/2006, our human study endpoints are aligned with European Food Safety Authority guidance for structure-function and health claims.
Electronic patient outcome assessments (eCOA) and EDC databases are encrypted with 256-bit AES algorithms, ensuring participant de-identification complies with the Spanish LOPDGDD and EU GDPR mandates.
Detailed insights regarding protocol handoff, sample shipment, regulatory transfer, and intellectual property safety.
Select your target research protocol, pre-clinical testing sequence, or analytical method package below to request technical documentation and quotes.
Schedule a technical consultation with our research team or request full assay feasibility data, method validation matrices, and CDMO production schedules tailored for the European life science market.
